Odonate Therapeutics, Inc. Proceeds from Common Stock Issued
Odonate Therapeutics, Inc. reported Proceeds from Common Stock Issued of $87.38 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2021-11-10
- Odonate Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2020-12-31 was -$1.00K, a 200.00% decline year-over-year.
- Odonate Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2019-12-31 was $1.00K.
- Odonate Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2019-09-30 was $17.39M.
- Odonate Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- Odonate Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2020 was $87.38M, a 35.32% decline from fiscal 2019.
- Odonate Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2019 was $135.10M, a 1271.81% increase from fiscal 2018.
- Odonate Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2018 was $9.85M, a 95.55% decline from fiscal 2017.
- Odonate Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2017 was $221.45M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $87.38M 10-K · filed 2021-02-23 | ||
| 2020-09-30 | $87.38M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $17.39M derived: sum of 2 quarters · filed 2021-02-23 | $135.10M 10-K · filed 2021-02-23 | |
| 2019-09-30 | $17.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $135.09M 10-Q · filed 2020-10-28 | ||
| 2019-06-30 | $117.70M 10-Q · filed 2020-07-30 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $0.00 derived: sum of 2 quarters · filed 2020-02-20 | $0.00 derived: sum of 3 quarters · filed 2020-02-20 | $9.85M 10-K · filed 2020-02-20 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $9.85M 10-Q · filed 2019-11-06 | $147.32M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $9.85M 10-Q · filed 2019-07-24 | $147.32M derived: sum of 3 quarters · filed 2019-07-24 | $221.31M derived: sum of 4 quarters · filed 2019-07-24 |
| 2018-03-31 | $9.85M 10-Q · filed 2019-04-25 | $147.32M derived: sum of 2 quarters · filed 2019-04-25 | $221.31M derived: sum of 3 quarters · filed 2019-04-25 | $221.29M derived: sum of 4 quarters · filed 2019-04-25 |
| 2017-12-31 | $137.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $211.46M derived: sum of 2 quarters · filed 2019-02-22 | $211.45M derived: sum of 3 quarters · filed 2019-02-22 | $221.45M 10-K · filed 2019-02-22 |
| 2017-09-30 | $73.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $73.97M derived: sum of 2 quarters · filed 2018-10-23 | $83.97M 10-Q · filed 2018-10-23 | |
| 2017-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30 | $9.99M 10-Q · filed 2018-07-30 | ||
| 2017-03-31 | $10.00M 10-Q · filed 2018-05-03 |